Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles

The commercially available rebamipide ophthalmic suspension (CA-REB) was approved for clinical use in patients with dry eye; however, the residence time on the ocular surface for the traditional formulations is short, since the drug is removed from the ocular surface through the nasolacrimal duct. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Noriaki, Ishii, Miyu, Seiriki, Ryotaro, Ogata, Fumihiko, Otake, Hiroko, Nakazawa, Yosuke, Okamoto, Norio, Kanai, Kazutaka, Kawasaki, Naohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076486/
https://www.ncbi.nlm.nih.gov/pubmed/32075200
http://dx.doi.org/10.3390/pharmaceutics12020155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076486/
https://www.ncbi.nlm.nih.gov/pubmed/32075200
http://dx.doi.org/10.3390/pharmaceutics12020155

Ejemplares similares